Q-omics provides the consensus-scored MTCO3P12 profile across patient tissues and cancer cell-line models. MTCO3P12 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, MTCO3P12 is differentially expressed in 8, with the highest sampling consensus in KIRC. Additionally, MTCO3P12 RNA expression shows 14,949 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight LUAD, KIRC, and KIRP as cancer lineages where MTCO3P12 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MTCO3P12 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MTCO3P12 survival associations across molecular data types. MTCO3P12 RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MTCO3P12 RNA expression–survival associations across cancer types. High MTCO3P12 expression shows unfavorable associations in LUAD and THYM, but favorable associations in KIRP, LUSC, CESC and ACC. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for MTCO3P12 RNA expression.
This table summarizes MTCO3P12 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for MTCO3P12. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MTCO3P12 shows lower tumor expression in KIRC, PAAD, KIRP, BRCA and ESCA and higher tumor expression in KICH. The KIRC box plot shows higher MTCO3P12 RNA expression in normal versus tumor tissue (log2 FC = −1.322, t-test p < 0.001).
This table shows molecular features associated with MTCO3P12 in patient tissues and cancer cell lines. In patient samples, MTCO3P12 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set.
